Curasight マネジメント

マネジメント基準チェック /24

Curasightの CEO はUlrich Krasilnikoffで、 Jan2016年に任命され、の在任期間は 8.83年です。は、会社の株式の19.25%を直接所有しており、その価値はDKK 45.18M 。経営陣と取締役会の平均在任期間はそれぞれ8.8年と8.8年です。

主要情報

Ulrich Krasilnikoff

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	8.8yrs
CEOの所有権	19.2%
経営陣の平均在職期間	8.8yrs
取締役会の平均在任期間	8.8yrs

経営陣の近況

Recent updates

Curasight (NGM:CURAS) Is Making Moderate Use Of Debt

Aug 29

CEO（最高経営責任者

Ulrich Krasilnikoff (57 yo)

8.8yrs

在職期間

Mr. Ulrich Alexander Krasilnikoff has been Chief Executive Officer, Chief Financial Officer and Executive Director at Curasight A/S since 2016. Mr. Krasilnikoff served as an Associate Partner at Capidea Ma...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Ulrich Krasilnikoff	CEO, CFO & Executive Director	8.8yrs	データなし	19.25% DKK 45.2m
Jacob Madsen	Co-Founder & Director CMC	11.8yrs	データなし	4.4% DKK 10.3m
Andreas Kjaer	Co-Founder	11.8yrs	データなし	29.09% DKK 68.3m
Hanne Jensen	Chief Development Officer & COO	2.8yrs	データなし	0.19% DKK 451.6k
Nic Gillings	Head of Quality Assurance & Regulatory Affairs	3.4yrs	データなし	データなし

8.8yrs

平均在職期間

59yo

平均年齢

経験豊富な経営陣: CURASの経営陣は経験豊富で経験豊富です（平均在職期間は8.8年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Ulrich Krasilnikoff	CEO, CFO & Executive Director	8.8yrs	データなし	19.25% DKK 45.2m
Andreas Kjaer	Co-Founder	11.8yrs	データなし	29.09% DKK 68.3m
Kirsten Drejer	Chairman of the Board	3.4yrs	データなし	0.019% DKK 45.2k
Lars Trolle	Independent Deputy Chairman of the Board	10.8yrs	データなし	2.84% DKK 6.7m
Charlotte Vedel	Independent Deputy Chairman of the Board	4.8yrs	データなし	0.19% DKK 451.6k

8.8yrs

平均在職期間

57yo

平均年齢

経験豊富なボード: CURASの取締役会は経験豊富であると考えられます ( 8.8年の平均在任期間)。

Curasight マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Less than half of directors are independent

Curasight A/S Announces Board Changes

Curasight A/S, Annual General Meeting, Mar 21, 2024

Curasight A/S, Annual General Meeting, Mar 24, 2022

Recent updates

Curasight A/S Announces Clinical Supply Agreement with Curium for uTREAT® Development and Commercialization

Curasight A/S Announces International Patent Application for uTREAT® to Broaden IP Protection

Curasight A/S Publishes Clinical Phase II Trial of uPAR-PET in Brain Cancer Patients; Data Supports Development of uTREAT for Brain Cancer

New major risk - Financial position

Curasight A/S to Report Q3, 2024 Results on Nov 21, 2024

Curasight (NGM:CURAS) Is Making Moderate Use Of Debt

New minor risk - Shareholder dilution

Curasight A/S to Report Q2, 2024 Results on Aug 22, 2024

Curasight A/S to Report Q3, 2024 Results on Jul 02, 2024

New major risk - Share price stability

New major risk - Financial position

Curasight A/S to Report Q1, 2024 Results on May 23, 2024

Less than half of directors are independent

Curasight A/S Announces Approval of Clinical Trial Application (CTA) for Phase 2 Trial with uTRACE in Prostate Cancer Patients

Curasight A/S Announces Board Changes

Curasight A/S has withdrawn its Follow-on Equity Offering in the amount of SEK 51.155712 million.

Curasight A/S, Annual General Meeting, Mar 21, 2024

Curasight A/S has filed a Follow-on Equity Offering in the amount of SEK 51.155712 million.

Curasight A/S to Report Fiscal Year 2023 Results on Feb 22, 2024

Curasight Gears Up for Phase II Study in Prostate Cancer

Curasight A/S to Report Q3, 2023 Results on Nov 24, 2023

New minor risk - Share price stability

Curasight A/S Reports Positive Preclinical Results with uTREAT[®] in lung cancer (NSCLC)

Curasight A/S Announces Positive Results from the Phase II Study of uTRACE in Brain Cancer Presented at the World Molecular Imaging Congress (WMIC) 2023 in Prague

Curasight A/S to Report Q2, 2023 Results on Aug 24, 2023

Curasight A/S Announces Positive Results in Upar-Pet/MR Phase II Study in Brain Cancer

Curasight A/S Reports Positive Preclinical Results with uTREAT in Aggressive Brain Cancer (Glioblastoma)

Curasight A/S to Report Fiscal Year 2022 Results on Feb 23, 2023

Curasight A/S Initiates Pre-Clinical Studies with uTREAT Therapy in Head and Neck Cancer and Neuroendocrine Tumors

Curasight A/S Announces Recruitment Completes in uPAR-PET Study in Brain Cancer

Curasight A/S, Annual General Meeting, Mar 24, 2022

Curasight A/S Announces Positive Data of uTREAT® in Glioblastoma Provides "Green Light" to Proceed with Next Steps

New 90-day high: kr.41.50

New 90-day high: kr.34.45

Curasight Announces Results from Phase II Study in Prostate Cancer to Be Published in the Journal of Nuclear Medicine

Curasight A/S to Report Q1, 2021 Results on May 20, 2021

Curasight A/S Initiates Pre-Clinical Study on Therapy in Brain Cancer and Signs CRO-Agreement

Curasight A/S has completed an IPO in the amount of DKK 32.688 million.

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24